Express Mail: EV 630723785 US Preliminary Amendment A Appl. No. TBA April 26, 2006

Amended Claims

1) (currently amended) An antiparasitic formulation, wherein:

the formulation characterized in that it comprises one or more spinosyns, as active ingredients, spinosyn(s) in combination with one or more compounds of a compound of formula (I) and/or salts thereof;

formula (I) corresponds in structure to:

$$W \longrightarrow (CH_2)_n(A)_p \longrightarrow R_2$$

$$R_3$$

$$R_4$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_3$$

and salts thereof, in which

Ar is 2,6-dichloro-4-trifluoromethylphenyl or 2-nitro-4-trifluoromethylphenyl;

A is S(O)_m, -CH=CH-CH=CH, O, or NH;

as to W and Z:

W is N, and Z is CR⁵; or

W is CR1, and Z is N or CR5;

R1 is hydrogen, optionally substituted alkyl, halogen, or R20S(O)q;

R² and R³ are <u>independently</u> hydrogen, <u>optionally substituted</u> alkyl, <u>optionally substituted</u> alkenyl, <u>optionally substituted</u> [[or]] alkynyl, each of which is optionally substituted, aryl, cyano, halogen, nitro, YR²⁰, S(O)₂NR⁸R⁹, CHO, NR⁸R⁹, or CYNR⁸R⁹;

R⁴ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, acyl, or optionally substituted alkoxycarbonyl;

R⁵ is hydrogen, alkyl, optionally substituted amino, or halogen;

R⁸ and R⁹ are <u>independently</u> the same or different and are hydrogen, optionally substituted alkyl, acyl, or aryl;

R²⁰ is optionally substituted alkyl;

Y is O or S;

Express Mail: EV 630723785 US Preliminary Amendment A Appl. No. TBA April 26, 2006

m is [[0]] zero, 1, or 2;
p is [[0]] zero or 1;
n is [[0]] zero, 1, or 2; [[and]]
q is [[0]] zero, 1, or 2; , and in which a)
any alkyl, alkoxy, or [[and]] alkylthio comprises groups is of 1 to 4 carbon atoms;
[[b)]]

any alkenyl or alkynyl comprises groups is of 2 to 5 carbon atoms; [[c)]]

the alkyl, alkoxy, alkylthio, alkenyl, or alkynyl portion of any substituted alkyl, alkoxy, alkylthio, alkenyl, or alkynyl [[group]] is substituted by one or more substituents independently of the same or different groups selected from the group consisting of halogen, YR²⁰, dihalocyclopropyl, cyano, nitro, optionally substituted amino, acyloxy, and aryl; [[d)]]

any aryl [[group]] is phenyl [[,]] optionally substituted [[,]] by halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, haloalkylsulphonyl, cyano, or nitro; [[e)]]

any acyl [[group]] is alkanoyl <u>comprising</u> [[of]] 1 to 4 carbon atoms, [[or]] alkylsulphonyl, or haloalkylsulphonyl; [[and f)]]

any optionally substituted amino $\frac{1}{2}$ is $\frac{1}{2}$ of $\frac{1}{2}$ and $\frac{1}{2}$ with the proviso that

R4 is not alkyl when:

W is CR¹, [[and]]
Z is CR⁵, and
n and p are both zero 0, R⁴ is not alkyl.

2) (currently amended) The formulation according to claim 1, wherein characterized in that the compound of formula (I) is 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole or a salt thereof (compound 22c).

Expréss Mail: EV 630723785 US Preliminary Amendment A Appl. No. TBA April 26, 2006

- 3) (currently amended) The formulation according to claim 1, wherein the formulation comprises or 2 characterized in that the spinosyns are a mixture of [[any]] two or more spinosyns spinosyn compounds.
- 4) (currently amended) The formulation according to claim 3, wherein characterized in that the mixture is spinosad.
- 5) (currently amended) The formulation according to any of claims claim 1, wherein the ratio of -4 characterized in that the one or more compounds compound of formula (I) (and/or salts thereof) to the [[and]] one or more spinosyns is from are present in a ratio of 1:10 to 10:1.
- 6) (currently amended) <u>A method of controlling an ectoparasite infestation</u>, wherein the method comprises simultaneously or sequentially administering: Use of one or more spinosyns, and at least

one <u>or more compounds of compound according to formula (I)</u>
recited in claim 1 (and/or salts thereof) as active ingredients in the
manufacture of a medicament for controlling an ectoparasite infestation
by administering the active ingredients in combination, either
simultaneously or sequentially.

7) (currently amended) The method [[Use]] according to claim 6, wherein the method comprises administering: active ingredients are

spinosad, and

5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole **or a salt thereof and spinosad**.

8) (currently amended) The method [[Use]] according to claim 6, [[or 7,]] wherein the one or more spinosyns and one or more compounds of at least one compound

Express Mail: EV 630723785 US

Preliminary Amendment A

Appl. No. TBA April 26, 2006

according to formula (I) (and/or salts thereof) are administered medicament is for controlling an ectoparasite infestation by administering the active ingredients simultaneously.

- 9) (currently amended) The method [[Use]] according to claim 8, wherein the one or more spinosyns and one or more compounds of formula (I) (and/or salts thereof) are medicament comprises the active ingredients in a single preparation.
- 10) (currently amended) The method [[Use]] according to claim 6, wherein the ectoparasites are ticks.
- 11) (currently amended) The method [[Use]] according to claim 6, wherein the ectoparasites are fleas.

Please add the following new claims:

- 12) (new) The formulation according to claim 2, wherein the ratio of the 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) to the one or more spinosyns is from 1:10 to 10:1.
- 13) (new) The formulation according to claim 2, wherein the formulation comprises a mixture of two or more spinosyns.
- 14) (new) The formulation according to claim 3, wherein the ratio of the one or more compounds of formula (I) (and/or salts thereof) to the two or more spinosyns is from 1:10 to 10:1.
- 15) (new) The formulation according to claim 4, wherein the ratio of the one or more compounds of formula (I) (and/or salts thereof) to the spinosad is from 1:10 to 10:1.

Express Mail: EV 630723785 US

Preliminary Amendment A

Appl. No. TBA April 26, 2006

16) (new) The formulation according to claim 13, wherein the ratio of the 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) to the two or more spinosyns is from 1:10 to 10:1.

- 17) (new) The formulation according to claim 13, wherein the mixture is spinosad.
- 18) (new) The formulation according to claim 17, wherein the ratio of the 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) to the spinosad is from 1:10 to 10:1.
- 19) (new) The method according to claim 7, wherein the spinosad and 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) are administered simultaneously.
- 20) (new) The method according to claim 19, wherein spinosad and 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) are in a single preparation.
- 21) (new) A use of one or more spinosyns in combination with one or more compounds of formula (I) (and/or salts thereof) recited in claim 1, wherein the use comprising making a medicament for controlling an ectoparasite infestation by simultaneously or sequentially administering the one or more spinosyns in combination with one or more compounds of formula (I) (and/or salts thereof).